^
    Back
    Association details:
    Biomarker:KMT2D mutation
    Cancer:Triple Negative Breast Cancer
    Drug:cyclophosphamide (Alkylating agent) +
    epirubicin (Topoisomerase II inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    AACR 2022
    Title:

    5084 - KMT2D and PIK3CA mutation as potential factors to predict adjuvant chemotherapy efficacy in surgical triple negative breast cancer

    Published date:
    03/09/2022
    Excerpt:
    A total of 386 TNBC patients were randomized 1:1 to receive either six cycles of paclitaxel + cisplatin (TP) or four cycles of epirubicin + cyclophosphamide followed by four cycles of docetaxel (EC-T) adjuvant chemotherapy after surgery (NCT01150513)...KMT2D mutation (15%, 11/75) display worse DFS for patients treated with EC-T platinum-free group (HR=3.0, p=0.039).